Global Oncology Academy

The Role of PARP Inhibitors in Metastatic Breast Cancer

ReachMD Healthcare Image

    PARP inhibitors are a type of targeted therapy used in the treatment of MBC by blocking the activity of an enzyme. Read more.

    • Overview

      Two PARP inhibitors, olaparib and talazoparib, have been approved for the treatment of metastatic breast cancer (MBC) giving patients a promising new treatment option. Dive into the details of the trials for each therapy.

    Facebook Comments



    We’re glad to see you’re enjoying Global Oncology Academy…
    but how about a more personalized experience?

    Register for free